Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro

Neuroendocrinology

Volumn 73, Issue 5, 2001, Pages 344-351

  Tulipano, Giovanni ^a   Bonfanti, Carlo ^b   Milani, Gabriella ^a   Billeci, Bruno ^d   Bollati, Angelo ^c   Cozzi, Renato ^g   Maira, Giulio ^e   Murphy, William A ^h   Poiesi, Claudio ^b   Turazzi, Sergio ^f   Giustina, Andrea ^a  

^a Endocrine Section   (Italy)

^b Institute of Microbiology   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d Divisions of Neurosurgery Hospital of Treviso   (Italy)

^e FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^f MAGGIORE HOSPITAL   (Italy)

^g OSPEDALE NIGUARDA CA GRANDA   (Italy)

^h TULANE UNIVERSITY   (United States)

Author keywords

Adenomas; Clinical neuroendocrinology; Growth hormone; Somatostatin; Somatostatin analogs; Somatostatin receptors

Indexed keywords

ANGIOPEPTIN; BIM 23268; CYCLO(CYSTEINYLPHENYLALANYLPHENYLALANYL DEXTRO TRYPTOPHYLLYSYLTHREONYLPHENYLALANYLCYSTEINYL)AMIDE; DEXTRO PHENYLALANINE CYCLO(CYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLSERYLCYSTEINYL)NAL AMIDE; G PROTEIN COUPLED RECEPTOR; HUMAN GROWTH HORMONE; NC 4 28B; OCTREOTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ACROMEGALY; ADENOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RESPONSE; DRUG SELECTIVITY; FEMALE; GROWTH HORMONE RELEASE; HORMONE INHIBITION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOMA; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 17844365283     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054651     Document Type: Article

References (33)

1. Somatostatin and its receptor family
2. Neuroendocrine control of growth hormone secretion
3. Somatostatin receptors in the central nervous system
4. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors
5. Somatostatin receptor subtype gene expression in pituitary adenomas
6. Expression of three somatostatin receptor subtypes in pituitary adenomas: Evidence for preferential SSTR5 expression in the mammosomatotroph lineage
7. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors
8. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinoma
9. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly
10. The pharmacological aspects of the treatment of acromegaly
11. Receptor-specific somatostatin analogs: Correlations with biological activity
12. Surgical management of acromegaly
13. Octreotide treatment of acromegaly: A randomized, multicenter study
14. Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study
15. Clinical review. Recent advances in pathogenesis, diagnosis and management of acromegaly
16. Medical therapy for acromegaly
17. Somatostatin receptor subtype specificity in human fetal pituitary cultures: Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone and prolactin regulation
18. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors
19. Human somatostatin receptor subtypes in acromegaly: Distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes
20. Cloned somatostatin receptors: Identification of subtypes selective peptides and demonstration of high affinity binding of linear peptides
21. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5
22. Inhibitory effects of galanin on growth hormone (GH) release in cultured GH-secreting adenoma cells: Comparative study with octreotide, GH-releasing hormone and thyrotropin-releasing hormone
23. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly
24. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the humans
25. Criteria for cure of acromegaly: A consensus statement
26. Long term treatment of 189 acromegalic patients with the somatostatin analogue octreotide
27. Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study
28. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status
29. Molecular biology of somatostatin receptors
30. Sandostatin LAR in acromegalic patients: Long-term treatment
31. Exercise-induced microalbuminuria in patients with active acromegaly: Acute effects of slow-release lanreotide, a long-acting somatostatin analog
32. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
33. An open, phase III study of lanreotide (Somatuline PR) in the treatment of acromegaly